Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Chinese Patent Office
Johnson and Johnson
Farmers Insurance
Colorcon
Julphar
Accenture
Cipla
Healthtrust

Generated: December 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DALIRESP

« Back to Dashboard

Clinical Trials for Daliresp

Trial ID Title Status Sponsor Phase Summary
NCT01433666 Roflumilast and Cognition Completed ZonMw: The Netherlands Organisation for Health Research and Development Phase 2 The aim of the current project is to validate PDE4 inhibitors as a target for cognition enhancers (proof-of-concept) using a translational behaviour-EEG approach. The project will demonstrate whether memory, but also attention, information processing or executive function improves with the PDE4 inhibitor roflumilast in healthy humans.
NCT01433666 Roflumilast and Cognition Completed Maastricht University Medical Center Phase 2 The aim of the current project is to validate PDE4 inhibitors as a target for cognition enhancers (proof-of-concept) using a translational behaviour-EEG approach. The project will demonstrate whether memory, but also attention, information processing or executive function improves with the PDE4 inhibitor roflumilast in healthy humans.
NCT01443845 Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Completed Forest Laboratories Phase 4 To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.
NCT01572948 A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD) Completed University of Alabama at Birmingham N/A The purpose of the study is to propose that roflumilast is associated with meaningful reductions in biomarkers of pulmonary inflammation and sputum neutrophilia, including confirmation of previously described results, and correlate these findings with improvement in pulmonary function, sputum scores, and quality of life in stable moderate to severe COPD. The investigators aim to demonstrate this regardless of concomitant medication use, including inhaled corticosteroids. Additionally, the investigators hope to provide a mechanistic pathway by which these effects occur.
NCT01765192 Roflumilast Plus Montelukast in Adults With Severe Asthma Completed Takeda Phase 2 The purpose of this study is to evaluate the effect of roflumilast alone and in combination with montelukast on forced expiratory volume in 1 second (FEV1) in patients with inadequately controlled asthma.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Daliresp

Condition Name

Condition Name for Daliresp
Intervention Trials
COPD 5
Asthma 2
Chronic Obstructive Lung Diseases 1
Lung Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Daliresp
Intervention Trials
Pulmonary Disease, Chronic Obstructive 3
Lung Diseases, Obstructive 2
Lung Diseases 2
Asthma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Daliresp

Trials by Country

Trials by Country for Daliresp
Location Trials
United States 54
Canada 5
Argentina 5
Mexico 3
Serbia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Daliresp
Location Trials
Texas 3
Alabama 2
Maryland 2
New York 2
North Carolina 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Daliresp

Clinical Trial Phase

Clinical Trial Phase for Daliresp
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 2 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Daliresp
Clinical Trial Phase Trials
Completed 7
Recruiting 4
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Daliresp

Sponsor Name

Sponsor Name for Daliresp
Sponsor Trials
Forest Laboratories 3
Johns Hopkins University 2
University of Cincinnati 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Daliresp
Sponsor Trials
Other 16
Industry 4
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Fish and Richardson
Baxter
Farmers Insurance
Federal Trade Commission
Accenture
Cantor Fitzgerald
Argus Health
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.